Theodore W Laetsch Selected Research

tisagenlecleucel

12/2022	Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy.
1/2022	Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia.
1/2022	Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia.
1/2022	Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.
1/2022	Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia.
12/2021	Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma.
11/2021	Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia.
1/2021	Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia.
1/2021	Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy.
11/2019	Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT).

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Theodore W Laetsch Research Topics

Disease

34	Neoplasms (Cancer) 09/2022 - 09/2016
22	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 12/2022 - 01/2018
5	Cytokine Release Syndrome 01/2022 - 01/2018
5	Neuroblastoma 01/2022 - 09/2016
4	Sarcoma (Soft Tissue Sarcoma) 11/2018 - 10/2016
3	Neoplasm Metastasis (Metastasis) 01/2022 - 01/2022
3	Genetic Translocation (Chromosomal Translocation) 01/2022 - 01/2019
3	Hyperthermia 01/2020 - 01/2016
2	Leukemia 10/2022 - 01/2022
2	Central Nervous System Neoplasms 01/2022 - 01/2021
2	Germ Cell and Embryonal Neoplasms (Germ Cell Tumor) 01/2022 - 01/2018
2	Infections 01/2021 - 01/2021
2	Rhabdomyosarcoma 01/2021 - 01/2018
2	Nausea 01/2020 - 01/2018
2	Microsatellite Instability 01/2020 - 11/2017
2	Fibrosarcoma 01/2020 - 01/2018
1	Hematologic Neoplasms (Hematological Malignancy) 12/2022
1	Hypokalemia 10/2022
1	Febrile Neutropenia 10/2022
1	Tumor Lysis Syndrome 10/2022
1	Mucositis 10/2022
1	Adenocarcinoma 01/2022
1	Acinar Cell Carcinoma 01/2022
1	Residual Neoplasm 01/2022
1	Thyroid Neoplasms (Thyroid Cancer) 01/2022
1	Down Syndrome (Down's Syndrome) 01/2022
1	Ewing Sarcoma (Sarcoma, Ewing) 01/2022
1	Medulloblastoma 01/2022
1	Alveolar Rhabdomyosarcoma 01/2022
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 12/2021
1	Hemorrhage 01/2021
1	Pinealoma (Pineoblastoma) 01/2021
1	Thrombocytopenia (Thrombopenia) 01/2021
1	Neurofibrosarcoma (MPNST) 12/2020
1	Lymphoma (Lymphomas) 01/2020
1	Long Term Adverse Effects 01/2020
1	Tics (Tic) 01/2020

Drug/Important Bio-Agent (IBA)

14	tisagenlecleucelIBA 12/2022 - 01/2018
13	Chimeric Antigen ReceptorsIBA 12/2022 - 01/2018
13	larotrectinibIBA 01/2022 - 01/2018
9	Phosphotransferases (Kinase)IBA 01/2022 - 01/2018
7	TropomyosinIBA 01/2022 - 01/2018
7	Pharmaceutical PreparationsIBA 01/2021 - 01/2019
4	Proteins (Proteins, Gene)FDA Link 09/2022 - 01/2017
3	Alanine Transaminase (SGPT)IBA 10/2022 - 01/2020
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2022 - 10/2022
2	entrectinibIBA 01/2022 - 01/2021
2	Biomarkers (Surrogate Marker)IBA 01/2022 - 12/2020
2	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 10/2019
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2022 - 01/2022
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021 - 01/2020
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2020 - 01/2018
2	tocilizumab (atlizumab)FDA Link 01/2019 - 01/2018
1	fludarabineIBA 12/2022
1	temsirolimus FDA Link 10/2022
1	TOR Serine-Threonine KinasesIBA 10/2022
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 10/2022
1	Etoposide (VP 16)FDA LinkGeneric 10/2022
1	CrizotinibIBA 09/2022
1	Tyrosine Kinase InhibitorsIBA 09/2022
1	alpha-Fetoproteins (alpha-Fetoprotein)IBA 01/2022
1	Monoclonal AntibodiesIBA 01/2022
1	Tuberculin (PPD)IBA 01/2022
1	CD19 AntigensIBA 01/2022
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2022
1	Neuropilin-1IBA 01/2022
1	TB-403IBA 01/2022
1	CD19-specific chimeric antigen receptorIBA 01/2022
1	blinatumomabIBA 01/2022
1	RNA (Ribonucleic Acid)IBA 01/2022
1	tyrosine receptor (receptor, tyrosine)IBA 12/2021
1	olaratumabIBA 01/2021
1	crisamicin AIBA 01/2021
1	navitoclaxIBA 01/2021
1	venetoclaxIBA 01/2021
1	Irinotecan (Camptosar)FDA LinkGeneric 01/2021
1	Fibrinogen (Factor I)FDA Link 01/2021
1	Immunoglobulins (Immunoglobulin)IBA 01/2021
1	NucleotidesIBA 01/2021
1	Transcription Factors (Transcription Factor)IBA 01/2021
1	TransferasesIBA 01/2021
1	Vincristine (Oncovin)FDA LinkGeneric 01/2021
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2020
1	trametinibIBA 12/2020
1	AZD 6244IBA 12/2020
1	Investigational DrugsIBA 05/2020
1	Contrast MediaIBA 01/2020
1	Liposomes (Liposome)IBA 01/2020
1	liposomal doxorubicin (Doxil)FDA Link 01/2020
1	Decitabine FDA Link 01/2020
1	Vorinostat FDA Link 01/2020

Therapy/Procedure

19	Therapeutics 01/2022 - 09/2016
10	Drug Therapy (Chemotherapy) 12/2022 - 09/2016
4	Immunotherapy 01/2022 - 01/2019
2	Transplantation 11/2019 - 01/2019
2	Extracorporeal Shockwave Therapy 10/2016 - 01/2016
1	Stem Cell Transplantation 01/2021
1	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2021
1	Investigational Therapies (Experimental Therapy) 05/2020
1	Microbubbles 01/2020